RNA

BostonGene Recognized as Designated Laboratory for the ComboMATCH Precision Medicine Clinical Trial

Retrieved on: 
Tuesday, March 26, 2024
Technology, Clinical Trials, Health Technology, Software, Biotechnology, Health, Pharmaceutical, Artificial Intelligence, Oncology, NCI, Combination, Gene, ECOG, Physician, Patient, Malignancy, NGS, Biomarker, Research, DNA, RNA, Tumor microenvironment, National Cancer Institute, WES, Cancer, MD, Medicine, Microsatellite instability, Clinical trial, RNA-Seq, Bangladesh Technical Education Board, Drug resistance

BostonGene , a leading provider of AI-driven, molecular and immune profiling solutions, today announced its participation in the Molecular Analysis for Combination Therapy Choice (ComboMATCH) precision medicine initiative as a designated laboratory.

Key Points: 
  • BostonGene , a leading provider of AI-driven, molecular and immune profiling solutions, today announced its participation in the Molecular Analysis for Combination Therapy Choice (ComboMATCH) precision medicine initiative as a designated laboratory.
  • ComboMATCH is a follow-up to the largest precision medicine clinical trial, the National Cancer Institute (NCI)-MATCH trial.
  • Already a CAP-accredited and CLIA-certified lab, BostonGene will now serve as a designated NGS laboratory for ComboMATCH.
  • “Our participation in the ComboMATCH trials underscores our commitment to advancing precision cancer medicine,” says Nathan Fowler, MD, Chief Medical Officer at BostonGene.

Key Charpentier/Doudna CRISPR Patent Upheld by China National Intellectual Property Administration

Retrieved on: 
Tuesday, March 26, 2024
Research, Legal, Medical Devices, Patent Law, Genetics, Professional Services, Biotechnology, Pharmaceutical, Health, Science, Trade, CVC, Patent, RNA, CNIPA, Emmanuelle, University, Genomics, CRISPR, Eukaryote, Intellectual property, Cas9

ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier, today announced its patent CN201380038920.6 was upheld by the China National Intellectual Property Administration (CNIPA) in response to an invalidation challenge.

Key Points: 
  • ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier, today announced its patent CN201380038920.6 was upheld by the China National Intellectual Property Administration (CNIPA) in response to an invalidation challenge.
  • The decision to uphold the patent right in China follows a recent decision by the Japanese Patent Office earlier this year to uphold JP6692856, also part of the CVC portfolio1.
  • The decision by the CNIPA, fully upholding the patent, further demonstrates its validity and value as part of the patent collection for use of the CRISPR/Cas9 technology.
  • Michael Arciero, Vice-President of Intellectual Property and Commercial Development, ERS Genomics, said: “The decision by the CNIPA is testament to the strength of the foundational CVC CRISPR/Cas9 patent portfolio.

Watchmaker Genomics Launches Watchmaker mRNA Library Prep Kits - Featuring a Rapid Workflow and Sensitive mRNA Detection

Retrieved on: 
Tuesday, March 26, 2024
Medical Supplies, Medical Devices, Health, Genetics, Other Health, Biotechnology, Watchmaker, Polaris, Genomics, RNA, DNA, Gene expression, Messenger, Small RNA, Vaccine

Watchmaker Genomics, a supplier of innovative products for molecular analysis, announced the launch of the Watchmaker mRNA Library Prep Kit – designed to streamline and accelerate mRNA library preparation, offering both speed and sensitivity to the genomics community.

Key Points: 
  • Watchmaker Genomics, a supplier of innovative products for molecular analysis, announced the launch of the Watchmaker mRNA Library Prep Kit – designed to streamline and accelerate mRNA library preparation, offering both speed and sensitivity to the genomics community.
  • The Watchmaker mRNA Library Prep Kit generates high-quality mRNA libraries in under 5 hours with fewer handling and purification steps.
  • Additionally, it delivers exceptionally sensitive and accurate gene expression data, enabling researchers to uncover valuable biological insights.
  • "We are thrilled to make this kit widely available," said Brian Kudlow, Chief Scientific Officer at Watchmaker.

Intranasal Delivery of shRNA Edits to Silence 5-HT2A Receptor Shows Promise in Enhancing Memory and Alleviating Anxiety

Retrieved on: 
Thursday, March 21, 2024
Science, Biotechnology, Research, Pharmaceutical, Health, Mental Health, Genetics, Clinical Trials, Depression, Brain, Dementia, Rat, BBB, Memory, Central nervous system, Public, RNA, Mouse, Traffic barrier, Anxiety, Translational Psychiatry, MCI, Neurological disorder, DSM-IV codes, HTR2A, Intrinsic termination, Therapy, Optimism, Cas9, Vaccine

In a groundbreaking study, they successfully used a non-invasive intranasal delivery platform to administer short-hairpin RNA (shRNA) that targets the 5-HT2A receptor resulting in long-lasting improvements in memory and reduced anxiety in animal models.

Key Points: 
  • In a groundbreaking study, they successfully used a non-invasive intranasal delivery platform to administer short-hairpin RNA (shRNA) that targets the 5-HT2A receptor resulting in long-lasting improvements in memory and reduced anxiety in animal models.
  • Neurological disorders such as Mild Cognitive Impairment (MCI), depression, and anxiety disorders pose significant challenges to public health worldwide.
  • In this study, the researchers designed shRNA sequences to specifically target and silence the human HTR2A gene, which is associated with anxiety and memory.
  • The ability to bypass the blood-brain barrier using intranasal delivery opens up new avenues for precision-based therapeutics in neurological disorders."

Celanese and Secarna Pharmaceuticals Enter into RNA Research Collaboration for Long-Acting Antisense Therapies

Retrieved on: 
Wednesday, March 20, 2024
Research, General Health, Pharmaceutical, Oncology, Data Management, Technology, Infectious Diseases, Science, Chemicals, Plastics, Biotechnology, Manufacturing, Health, CE, Asos, Drug discovery, Central nervous system, Patient, Corporation, Ophthalmology, RNA, CBO, Protein, Drug development, Medical device

Celanese Corporation (NYSE: CE), a global specialty materials and chemical company, and Secarna Pharmaceuticals GmbH & Co. KG, a leading independent European antisense drug discovery and development company, today announced a research collaboration for the development of long-acting implants that deliver antisense oligonucleotides (ASOs).

Key Points: 
  • Celanese Corporation (NYSE: CE), a global specialty materials and chemical company, and Secarna Pharmaceuticals GmbH & Co. KG, a leading independent European antisense drug discovery and development company, today announced a research collaboration for the development of long-acting implants that deliver antisense oligonucleotides (ASOs).
  • “Collaborating with Secarna allows us to develop an innovative implant that has the potential to significantly change the way disease-modifying ASO therapies are administered,” said Cyonna Holmes, global business strategy leader for Ophthalmology and RNA at Celanese.
  • With several high value and innovative programs, Secarna has validated its platform in various indications such as cardiometabolic, immune-oncology, fibrotic/inflammatory diseases and the central nervous system.
  • “We are looking forward to partnering with Celanese to combine our industry-leading ASO platform with their VitalDose® drug delivery technology,” said Konstantin Petropoulos, CBO of Secarna Pharmaceuticals.

Elegen Launches ENFINIA™ DNA Enhancement for Rapid Synthesis of Highly Complex DNA

Retrieved on: 
Wednesday, March 20, 2024
Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Genetics, SV40, Associate, GSK, NGS, RNA, DNA, EAP, Messenger, Cauliflower mosaic virus, Doctor of Philosophy, Lentivirus, Therapy, IRES, Access, Orbital, IVT, Vaccine

This upgrade to ENFINIA DNA sets a new standard for DNA manufacturing, providing an industry-leading combination of speed, length, NGS-verified accuracy and complexity.

Key Points: 
  • This upgrade to ENFINIA DNA sets a new standard for DNA manufacturing, providing an industry-leading combination of speed, length, NGS-verified accuracy and complexity.
  • EAP partners received long and very complex DNA sequences that were either rejected by other suppliers or would have taken months to synthesize.
  • Elegen commercially launched ENFINIA DNA in Q1 2023 , delivering NGS-verified, linear DNA up to 7kb in 6 to 8 business days.
  • This latest enhancement of ENFINIA DNA to produce high-complexity DNA marks another step in the company’s mission to develop innovative solutions for DNA manufacturing, including even longer DNA, plasmid DNA and clinical-grade DNA production.

Demeetra and Indiana University Biopesticide Platform Combining Gene Editing and Synthetic Biology Selected as a MDPI Journal Editor’s Choice Article

Retrieved on: 
Wednesday, March 20, 2024
Science, Other Science, Biotechnology, Research, Health, University, Genetics, Education, MDPI, Generation, Gene editing, Medicine, Saccharomyces cerevisiae, Transposase, Synthetic biology, Sterilization, RNA, Gene, Female, Indiana University, Engineering, Disease, Male, Mosquito control, Plant, Publication, Transgene, SIT, RNA interference, Therapy, Multimedia, Cas9

A pioneering study, authored by scientists from Demeetra and Indiana University, has been selected for the MDPI Journals Editor's Choice Articles , highlighting the impact of advanced gene editing in synthetic biology to produce biopesticides.

Key Points: 
  • A pioneering study, authored by scientists from Demeetra and Indiana University, has been selected for the MDPI Journals Editor's Choice Articles , highlighting the impact of advanced gene editing in synthetic biology to produce biopesticides.
  • View the full release here: https://www.businesswire.com/news/home/20240320823585/en/
    Demeetra and Indiana University research on gene edited yeast biopesticide was featured on the front cover of Fermentation.
  • According to MDPI “Editor’s Choice articles are based on recommendations by the scientific editors of MDPI journals from around the world.
  • “We wanted to engineer the ideal yeast platform for stable RNAi expression,” said Dr. Corey Brizzee, Director of Gene Editing at Demeetra.

Capstan Therapeutics Announces $175M Oversubscribed Series B Financing

Retrieved on: 
Wednesday, March 20, 2024
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, General Health, Health, Polaris Partners, Cell, General partnership, Venture round, RNA, Messenger, Bristol Myers Squibb, MBA, Bayer, Therapy, OrbiMed, Immune system, Eli Lilly and Company, Series, Investment, Blood, Vaccine

Capstan Therapeutics, Inc. (“Capstan”), a biotechnology company dedicated to advancing in vivo reprogramming of cells through RNA delivery using targeted lipid nanoparticles (tLNP), today announced the successful closing of a $175M oversubscribed Series B financing.

Key Points: 
  • Capstan Therapeutics, Inc. (“Capstan”), a biotechnology company dedicated to advancing in vivo reprogramming of cells through RNA delivery using targeted lipid nanoparticles (tLNP), today announced the successful closing of a $175M oversubscribed Series B financing.
  • The Series B financing was led by RA Capital Management, with participation from new investors Forbion, Johnson & Johnson Innovation - JJDC, Mubadala Capital, Perceptive Advisors, and Sofinnova Investments.
  • The proceeds from the Series B financing will be used to advance CPTX2309, Capstan’s lead in vivo chimeric antigen receptor T cell (CAR-T) candidate, to early clinical proof-of-concept in autoimmune disorders, and to further develop Capstan’s tLNP pipeline.
  • “This Series B financing brings together an exceptional syndicate of investors that recognize the potential of Capstan’s in vivo CAR-T technology,” said Laura Shawver, Ph.D., President and Chief Executive Officer of Capstan.

Portal Biotechnologies Announces $5M Pre-Seed Round Led By Pear VC

Retrieved on: 
Tuesday, March 19, 2024
Other Manufacturing, Other Science, Technology, Research, General Health, Engineering, Manufacturing, Pharmaceutical, Other Professional Services, Medical Devices, Health Technology, Finance, Genetics, Nanotechnology, Professional Services, Artificial Intelligence, Biotechnology, Other Technology, Health, Hardware, Science, Innovation Center station, Gene editing, Cell, BRIC, RNA, Pear VC, Conscience, Capital, Messenger, Hope, Genome, Doctor of Philosophy, Bayer, Antibody, Kendall Square, CRISPR, Drug development, Multimedia, Small RNA, Silicon, Fine chemical

Today, Portal Biotechnologies, Inc. (“Portal”), a cell engineering platform company, announced a $5M pre-seed round led by Pear VC, with participation from Conscience VC and 10x Capital.

Key Points: 
  • Today, Portal Biotechnologies, Inc. (“Portal”), a cell engineering platform company, announced a $5M pre-seed round led by Pear VC, with participation from Conscience VC and 10x Capital.
  • Portal is committed to ensuring broad accessibility of its platform to enable a variety of research and therapeutic applications.
  • The company was founded by Armon Sharei, Ph.D., founder and former CEO of SQZ Biotechnologies.
  • “We are very excited to join the Portal team and support their mission to solve one of the field's major long-standing challenges,” said Eddie Eltoukhy, Partner and lead investor from Pear VC.

DNAnexus to Showcase the Power of High-Value Multi-Omics Data at the Precision Medicine in IBD Summit

Retrieved on: 
Monday, March 18, 2024
Hardware, Health Technology, Data Management, Technology, Nanotechnology, Pharmaceutical, General Health, Professional Services, Genetics, Biotechnology, Science, Software, Data Analytics, Internet, Research, Health, Cloud, Drug discovery, Tissue, RNA, Acquisition, Personalized medicine, IBD, Medicine, Inflammatory bowel disease, CLIA, Ecosystem, Ovation, Whole genome sequencing, Privacy, Pharmaceutical industry

The company is hosting a luncheon presentation that will focus on its collaboration with Ovation , an omics data company committed to accelerating the development of precision medicine, to help streamline large-scale omics data analysis.

Key Points: 
  • The company is hosting a luncheon presentation that will focus on its collaboration with Ovation , an omics data company committed to accelerating the development of precision medicine, to help streamline large-scale omics data analysis.
  • DNAnexus’ collaboration is initially focused on Ovation’s inflammatory bowel disease omics data, which includes whole genome sequencing and RNA sequencing on normal and diseased tissues linked to longitudinal clinical data.
  • Ovation’s omics data is derived from its extensive biobank of more than 1.6 million consented samples.
  • The secure and scalable DNAnexus Precision Health Data Cloud helps researchers manage, analyze, and collaborate on the complex multimodal data.